Siegfried Plans Production Plant in Nantong, Eastern China  

Siegfried, a Swiss pharmaceuticals custom manufacturer, plans the erection of a production plant in Nantong, eastern China, supported by NETDA, a Chinese development organization. The development of production capacity in China will strengthen Siegfried's competitive position and create additional sales opportunities in Asia. The company is exploring further cooperation agreements with Chinese companies
   In an initial phase, Siegfried will invest in a plant producing active pharmaceutical ingredients and intermediates. In China also, the company will produce in accordance with high quality standards. The planned facility allows for production in accordance with internationally recognized standards of current good manufacturing practice (cGMP). The available land permits extension in a second phase to include, for instance, the production of finished dosage forms.
   Investment in the development of the new location will be stepwise. NETDA, Siegfried's cooperation partner, will provide a fully functional industrial infrastructure. NETDA also provides support to Siegfried in obtaining the required authorizations and licenses. Production is to commence in 2014.